{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:26:47Z","timestamp":1787873207294,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Endocrine & Metabolism Research Institute at Tehran University of Medical Sciences , Iran","award":["1402-01-477-64018"],"award-info":[{"award-number":["1402-01-477-64018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02506-9","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:01:23Z","timestamp":1742302883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the hypercholesterolemia care cascade and compliance with NCEP-ATP III guidelines in Iran based on the WHO STEPS survey"],"prefix":"10.1186","volume":"24","author":[{"given":"Shirin","family":"Djalalinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moein","family":"Yoosefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvenaz","family":"Salahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Shokri","family":"Varniab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Golestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou","family":"Dilmaghani-Marand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Mahdi","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Farzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Azadnajafabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Abdolhamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Haghshenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arefeh Alipour","family":"Derouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh Momen Nia","family":"Rankohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Farzadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2506_CR1","doi-asserted-by":"publisher","unstructured":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. May 18 2024;403(10440):2100\u20132132. https:\/\/doi.org\/10.1016\/s0140-6736(24)00367-2","DOI":"10.1016\/s0140-6736(24)00367-2"},{"key":"2506_CR2","doi-asserted-by":"publisher","unstructured":"Fatollahzade M, Bastan M-M, Shaabanian M, et al. Sex disparity in the burden of NCDs and its four main subgroups in Iran 1990\u20132019: a systematic analysis from the global burden of disease study 2019. J Diab Metab Disord. 2024\/09\/09 2024. https:\/\/doi.org\/10.1007\/s40200-024-01489-1","DOI":"10.1007\/s40200-024-01489-1"},{"key":"2506_CR3","unstructured":"UN. Sustainable development goals. 2030. Available at: https:\/\/sustainabledevelopment.un.org\/?menu513002017."},{"key":"2506_CR4","doi-asserted-by":"publisher","unstructured":"Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990\u20132015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018;63(Suppl 1):137\u2013149. https:\/\/doi.org\/10.1007\/s00038-017-1012-3","DOI":"10.1007\/s00038-017-1012-3"},{"issue":"6","key":"2506_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jacl.2018.08.001","volume":"12","author":"Z Aryan","year":"2018","unstructured":"Aryan Z, Mahmoudi N, Sheidaei A, et al. The prevalence, awareness, and treatment of lipid abnormalities in Iranian adults: Surveillance of risk factors of noncommunicable diseases in Iran 2016. J Clin Lipidol. 2018;12(6):1471-1481.e4. https:\/\/doi.org\/10.1016\/j.jacl.2018.08.001.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2506_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","volume":"44","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol. 2004;44(3):720\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"2506_CR7","doi-asserted-by":"publisher","unstructured":"Pencina MJ, Navar-Boggan AM, D'Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014\/04\/10 2014;370(15):1422\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa1315665","DOI":"10.1056\/NEJMoa1315665"},{"issue":"4","key":"2506_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archinte.160.4.459","volume":"160","author":"TA Pearson","year":"2000","unstructured":"Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459\u201367. https:\/\/doi.org\/10.1001\/archinte.160.4.459.","journal-title":"Arch Intern Med"},{"issue":"8","key":"2506_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0002-9343(02)01303-7","volume":"113","author":"JP Frolkis","year":"2002","unstructured":"Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002;113(8):625\u20139.","journal-title":"Am J Med"},{"key":"2506_CR10","doi-asserted-by":"publisher","unstructured":"Jafari A, Mirbehbahani SH, Golestani A, et al. Cardiometabolic risk factors trend in Iranian adults with hypertension over 15 years: findings of nationwide steps of 2007\u20132021. J Diab Metab Disord. 2024\/09\/23 2024. https:\/\/doi.org\/10.1007\/s40200-024-01498-0","DOI":"10.1007\/s40200-024-01498-0"},{"issue":"10","key":"2506_CR11","doi-asserted-by":"publisher","first-page":"e1003841","DOI":"10.1371\/journal.pmed.1003841","volume":"18","author":"ME Marcus","year":"2021","unstructured":"Marcus ME, Ebert C, Geldsetzer P, et al. Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: A cross-sectional study of nationally representative surveys. PLoS Med. 2021;18(10): e1003841. https:\/\/doi.org\/10.1371\/journal.pmed.1003841.","journal-title":"PLoS Med"},{"key":"2506_CR12","doi-asserted-by":"publisher","unstructured":"Khanali J, Ghasemi E, Rashidi M-M, et al. Prevalence of plasma lipid abnormalities and associated risk factors among Iranian adults based on the findings from STEPs survey 2021. Scient Rep. 2023\/09\/19 2023;13(1):15499. https:\/\/doi.org\/10.1038\/s41598-023-42341-5","DOI":"10.1038\/s41598-023-42341-5"},{"issue":"9","key":"2506_CR13","doi-asserted-by":"publisher","first-page":"e1363","DOI":"10.1016\/s2214-109x(23)00280-2","volume":"11","author":"S Ochmann","year":"2023","unstructured":"Ochmann S, von Polenz I, Marcus ME, et al. Diagnostic testing for hypertension, diabetes, and hypercholesterolaemia in low-income and middle-income countries: a cross-sectional study of data for 994 185 individuals from 57 nationally representative surveys. Lancet Glob Health. 2023;11(9):e1363\u201371. https:\/\/doi.org\/10.1016\/s2214-109x(23)00280-2.","journal-title":"Lancet Glob Health"},{"key":"2506_CR14","doi-asserted-by":"publisher","unstructured":"Djalalinia S, Azadnajafabad S, Ghasemi E, et al. Protocol Design for Surveillance of Risk Factors of Non\u2013communicable Diseases During the COVID-19 Pandemic: An Experience from Iran STEPS Survey 2021. Arch Iran Med. 2022\/9\/1 2022;25(9):634\u2013646. https:\/\/doi.org\/10.34172\/aim.2022.99","DOI":"10.34172\/aim.2022.99"},{"key":"2506_CR15","volume-title":"The WHO STEPwise approach to noncommunicable disease risk factor surveillance (STEPS), WHO STEPS Instrument (Core and Expanded)","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. The WHO STEPwise approach to noncommunicable disease risk factor surveillance (STEPS), WHO STEPS Instrument (Core and Expanded). Geneva: World Health Organization; 2015."},{"key":"2506_CR16","doi-asserted-by":"publisher","unstructured":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u2013980. https:\/\/doi.org\/10.1016\/s0140-6736(21)01330-1","DOI":"10.1016\/s0140-6736(21)01330-1"},{"key":"2506_CR17","doi-asserted-by":"crossref","unstructured":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143\u2013421.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/12485966\/.","DOI":"10.1161\/circ.106.25.3143"},{"key":"2506_CR18","doi-asserted-by":"publisher","unstructured":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486\u201397. https:\/\/doi.org\/10.1001\/jama.285.19.2486","DOI":"10.1001\/jama.285.19.2486"},{"key":"2506_CR19","doi-asserted-by":"crossref","unstructured":"Nejadghaderi SA, Ahmadi N, Rashidi M-M, Ghanbari A, Noori M, Abbasi-Kangevari M, Nasserinejad M, Rezaei N,Yoosefi M, Fattahi N: Physical activity pattern in Iran: Findings from STEPS 2021. Frontiers in Public Health 2022:10.","DOI":"10.3389\/fpubh.2022.1036219"},{"key":"2506_CR20","volume-title":"WHO STEPS Surveillance Manual","author":"WH Organization","year":"2017","unstructured":"Organization WH. WHO STEPS Surveillance Manual. Geneva, Switzerland: World Health Organization; 2017."},{"key":"2506_CR21","unstructured":"Lumley, Thomas 2023 survey: Analysis of Complex Survey Samples R package (https:\/\/cran.r-project.org\/package=survey) Research Resource Identifier (RRID): SCR_0128354.2\u20131."},{"key":"2506_CR22","unstructured":"RStudio Team 2023 RStudio: Integrated Development Environment for R RStudio, PBC Boston, MA http:\/\/www.rstudio.com Research Resource Identifier (RRID): SCR_000432."},{"key":"2506_CR23","unstructured":"R Core Team 2023 R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing Vienna, Austria https:\/\/www.R-project.org Research Resource Identifier (RRID): SCR_001905."},{"key":"2506_CR24","unstructured":"caret: Classification And REgression Training. R package version 7.0.1. Available from https:\/\/CRAN.R-project.org\/package=caret. RRID:SCR_021138."},{"key":"2506_CR25","doi-asserted-by":"publisher","unstructured":"Abbasi-Kangavari M, Masinaei M, Fattahi N, et al. Current inequities in smoking prevalence on district level in Iran: a systematic analysis on the STEPS survey. J Res Health Sci. 2021;22(1):e00540. https:\/\/doi.org\/10.34172\/jrhs.2022.75","DOI":"10.34172\/jrhs.2022.75"},{"key":"2506_CR26","doi-asserted-by":"publisher","unstructured":"MB AA, WA K. Cardiovascular diseases risk prediction using the Framingham risk score. Egypt J Occup Med. 2021;45(3):249\u2013264. https:\/\/doi.org\/10.21608\/ejom.2021.193283","DOI":"10.21608\/ejom.2021.193283"},{"key":"2506_CR27","doi-asserted-by":"publisher","unstructured":"D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P, Group ftCRP. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180\u2013187. https:\/\/doi.org\/10.1001\/jama.286.2.180","DOI":"10.1001\/jama.286.2.180"},{"issue":"520","key":"2506_CR28","first-page":"838","volume":"55","author":"PM Brindle","year":"2005","unstructured":"Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract. 2005;55(520):838\u201345.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"2506_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2022.05.003","volume":"16","author":"C Tran","year":"2022","unstructured":"Tran C, Vo V, Taylor P, Koehn DA, Virani SS, Dixon DL. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022;16(4):491\u20137.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"2506_CR30","doi-asserted-by":"publisher","first-page":"e008861","DOI":"10.1161\/circoutcomes.121.008861","volume":"15","author":"AR Zheutlin","year":"2022","unstructured":"Zheutlin AR, Derington CG, Herrick JS, et al. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022;15(12): e008861. https:\/\/doi.org\/10.1161\/circoutcomes.121.008861.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2506_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43044-021-00140-1","volume":"73","author":"H Taha","year":"2021","unstructured":"Taha H, Badran HM, Kandil H, et al. Egyptian practical guidance in lipid management 2020. Egypt Heart J. 2021;73(1):17. https:\/\/doi.org\/10.1186\/s43044-021-00140-1.","journal-title":"Egypt Heart J"},{"key":"2506_CR32","doi-asserted-by":"publisher","unstructured":"\u015een T, Din\u00e7 Asarc\u0131kl\u0131 L, G\u00fcven S, et al. Adherence to current dyslipidemia guideline in patients utilizing statins according to risk groups and gender differences: The AIZANOI Study. Anatol J Cardiol. 2024;28(6):273\u2013282. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2024.4218","DOI":"10.14744\/AnatolJCardiol.2024.4218"},{"key":"2506_CR33","doi-asserted-by":"publisher","unstructured":"Pirillo A, Norata GD. The burden of hypercholesterolemia and ischemic heart disease in an ageing world. Pharmacol Res. 2023\/07\/01\/ 2023;193:106814. https:\/\/doi.org\/10.1016\/j.phrs.2023.106814","DOI":"10.1016\/j.phrs.2023.106814"},{"key":"2506_CR34","doi-asserted-by":"crossref","unstructured":"Foley TR, Singh GD, Kokkinidis DG, Choy HK, Pham T, Amsterdam EA, Rutledge JC, Waldo SW, Armstrong EJ, Laird JR: High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc 2017:6.","DOI":"10.1161\/JAHA.117.005699"},{"key":"2506_CR35","doi-asserted-by":"crossref","unstructured":"Djalalinia S, Saeedi Moghaddam S, Sheidaei A, Rezaei N, Naghibi Iravani SS, Modirian M, Zokaei H, Yoosefi M, Gohari K, Kousha A, et al: Patterns of Obesity and Overweight in the Iranian Population: Findings of STEPs 2016. Front Endocrinol (Lausanne). 2020;11:42.","DOI":"10.3389\/fendo.2020.00042"},{"key":"2506_CR36","doi-asserted-by":"publisher","first-page":"1043894","DOI":"10.3389\/fendo.2022.1043894","volume":"13","author":"S Djalalinia","year":"2022","unstructured":"Djalalinia S, Yoosefi M, Shahin S, et al. The levels of BMI and patterns of obesity and overweight during the COVID-19 pandemic: Experience from the Iran STEPs 2021 survey. Front Endocrinol. 2022;13:1043894.","journal-title":"Front Endocrinol"},{"key":"2506_CR37","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998327293240729080250","author":"AH Behnoush","year":"2024","unstructured":"Behnoush AH, Khosravi S, Ziamanesh F, et al. Blood Pressure Control Among Diabetic Patients in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis. Curr Diabetes Rev. 2024. https:\/\/doi.org\/10.2174\/0115733998327293240729080250.","journal-title":"Curr Diabetes Rev"},{"key":"2506_CR38","doi-asserted-by":"publisher","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002","DOI":"10.1016\/j.jacc.2013.11.002"},{"issue":"24","key":"2506_CR39","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2506_CR40","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1186\/s12889-022-13615-w","volume":"22","author":"M Yousefi","year":"2022","unstructured":"Yousefi M, Dastan I, Alinezhad F, et al. Prevention and control of non-communicable diseases in iran: the case for Investment. BMC Public Health. 2022;22(1):1248. https:\/\/doi.org\/10.1186\/s12889-022-13615-w.","journal-title":"BMC Public Health"},{"key":"2506_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40200-017-0288-4","volume":"16","author":"N Peykari","year":"2017","unstructured":"Peykari N, Hashemi H, Dinarvand R, et al. National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. J Diabetes Metab Disord. 2017;16:3. https:\/\/doi.org\/10.1186\/s40200-017-0288-4.","journal-title":"J Diabetes Metab Disord"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02506-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:01:30Z","timestamp":1742302890000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02506-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2506"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02506-9","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol for the study was approved by the Research Ethics Committees of the Endocrine & Metabolism Research Institute at Tehran University of Medical Sciences, with the approval number IR.TUMS.EMRI.REC.1402.017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}